The majority of bleeding occasions had been spontaneous, and the most common sites of bleeding had been gastrointestinal. The numbers of bleeding occasions and other adverse occasions were consistent across the prespecified subgroups defined by age, sex, competition or ethnic group, type of palliative surgery, days from palliation to randomization, and status with respect to aspirin make use of before or during the study. Bleeding problems according to use or nonuse of concomitant aspirin therapy are summarized in Table S5 in the Supplementary Appendix. In per-protocol analyses, adverse events occurred in 260 patients in the clopidogrel group and 238 individuals in the placebo group .After three weeks, although the body mass index was increased in both groups, those receiving olanzapine/placebo demonstrated significantly greater weight increase than those receiving olanzapine/modafinil. Dr. Roerig notes that that this short-term study in healthy individuals has shown promise now, modafinil could be evaluated as a viable candidate for a larger now, more complex scientific trial to determine efficacy in an individual population. Dr. John Krystal, Editor of Biological Psychiatry and affiliated with both Yale University School of Medication and the VA Connecticut Healthcare System, agrees that further study can be warranted.